key: cord-0944757-1b6dkvdj
authors: Shiakolas, Andrea R.; Johnson, Nicole; Kramer, Kevin J.; Suryadevara, Naveenchandra; Wrapp, Daniel; Periasamy, Sivakumar; Pilewski, Kelsey A.; Raju, Nagarajan; Nargi, Rachel; Sutton, Rachel E.; Walker, Lauren; Setliff, Ian; Crowe, James E.; Bukreyev, Alexander; Carnahan, Robert H.; McLellan, Jason S.; Georgiev, Ivelin S.
title: Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking
date: 2021-06-30
journal: bioRxiv
DOI: 10.1101/2021.06.02.446813
sha: af0aa0a5b160e5d09d3e73deff751d8a3cd08296
doc_id: 944757
cord_uid: 1b6dkvdj

SARS-CoV-2 therapeutic antibody discovery efforts have met with notable success but have been associated with a generally inefficient process, requiring the production and characterization of exceptionally large numbers of candidates for the identification of a small set of leads. Here, we show that incorporating antibody–ligand blocking as part of LIBRA-seq, the high-throughput sequencing platform for antibody discovery, results in efficient identification of ultra-potent neutralizing antibodies against SARS-CoV-2. LIBRA-seq with ligand blocking is a general platform for functional antibody discovery targeting the disruption of antigen–ligand interactions.

8 RBD, and ACE2 competition. The 3D reconstruction revealed that 5317-4 binds to the RBD in 149 the "up" and "down" conformations, and its epitope partially overlaps the ACE2 binding footprint 150 ( Figure 2H-I) . In the RBD up position, 5317-4 binds near the receptor-binding motif at an angle 151 that appears to moderately clash with RBD-bound ACE2 ( Figure 2I) . Additionally, when bound 152 to the RBD in the down conformation, 5317-4 competes with ACE2 binding to the adjacent, 153 otherwise accessible RBD in the up position ( Figure 2I ). 5317-10 was of interest due to its 154 inconclusive epitope bin, as it bound to S1, but not to the individual RBD or NTD constructs 155 (Figure 2A) . The map revealed that 5317-10 binds a novel quaternary epitope that bridges an 156 RBD in the down position and the NTD of an adjacent protomer ( Figure 2H ). This mode of 157 recognition may prevent the RBD from transitioning into an ACE2-accessible up position, 

We used our previously described pipeline to use paired-end FASTQ files of oligo libraries as 309 input, process and annotate reads for cell barcode, UMI, and antigen barcode, and generate a 310 cell barcode -antigen barcode UMI count matrix 15, 16 . BCR contigs were processed using Cell 311

Ranger (10X Genomics) using GRCh38 as reference. Antigen barcode libraries were also 312 processed using Cell Ranger (10X Genomics). The overlapping cell barcodes between the two 313 libraries were used as the basis of the subsequent analysis. We removed cell barcodes that had 314 only non-functional heavy chain sequences as well as cells with multiple functional heavy chain 315 sequences and/or multiple functional light chain sequences, reasoning that these may be 316 multiplets. Additionally, we aligned the BCR contigs (filtered_contigs.fasta file output by Cell 317

Ranger, 10X Genomics) to IMGT reference genes using HighV-Quest 20 . The output of HighV-318

Quest was parsed using ChangeO 21 and merged with an antigen barcode UMI count matrix. 319

Finally, we determined the LIBRA-seq score for each antigen in the library by calculating the 320 centered-log ratios (CLR) of each antigen UMI count for each cell as previously described 15 To assess antibody binding, soluble protein was plated at 2 μg/mL overnight at 4°C. The next 363 day, plates were washed three times with PBS supplemented with 0.05% Tween-20 (PBS-T) 364 and coated with 5% milk powder in PBS-T. Plates were incubated for one hour at room 365 temperature and then washed three times with PBS-T. Primary antibodies were diluted in 1% 366 milk in PBS-T, starting at 10 μg/mL with a serial 1:5 dilution and then added to the plate. The 367

plates were incubated at room temperature for one hour and then washed three times in PBS-T. 368

The secondary antibody, goat anti-human IgG conjugated to peroxidase, was added at 1:10,000 369 dilution in 1% milk in PBS-T to the plates, which were incubated for one hour at room 370 temperature. Plates were washed three times with PBS-T and then developed by adding TMB 371 substrate to each well. The plates were incubated at room temperature for ten minutes, and 372 then 1N sulfuric acid was added to stop the reaction. Plates were read at 450 nm. 373

Data are represented as mean ± SEM for one ELISA experiment. ELISAs were repeated 2 or 374 more times. If ELISA replicates were inconsistent over more than three experiments, antibody 

Neutralizing Antibodies against SARS-CoV-2 and Other 567

Potently neutralizing and protective human antibodies against SARS-569

A neutralizing human antibody binds to the N-terminal domain of the Spike 571 protein of SARS-CoV-2

Broad neutralization of SARS-related viruses by human monoclonal 573 antibodies

Potent neutralizing antibodies from COVID-19 patients define 575 multiple targets of vulnerability

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection 577 from disease in a small animal model

Studies in humanized mice and convalescent humans yield a SARS-579

CoV-2 antibody cocktail

SARS-CoV-2 vaccines in development

Principles of Broad and Potent Antiviral Human Antibodies: Insights for 582

Broad diversity of neutralizing antibodies isolated from memory B cells 584 in HIV-infected individuals

Rational design of envelope identifies broadly neutralizing human 586 monoclonal antibodies to HIV-1

throughput sequencing of full-length immunoglobulin heavy and light chain genes

High-throughput sequencing of the paired human immunoglobulin 591 heavy and light chain repertoire

Barcode-enabled sequencing of plasmablast antibody repertoires in 593 rheumatoid arthritis

High-Throughput Mapping of B Cell Receptor Sequences to Antigen 595

Cross-reactive coronavirus antibodies with diverse epitope 597 specificities and Fc effector functions

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with 599

Monoclonal Antibodies to Disrupt Progression of Early Covid-19 Infection

REGN-COV2, a Neutralizing Antibody Cocktail

R)) tools for the nucleotide 605 analysis of immunoglobulin (IG) and T cell receptor (TR) V-(D)-J repertoires

IG mutations: IMGT/V-QUEST and IMGT/HighV-QUEST for NGS

Change-O: a toolkit for analyzing large-scale B cell immunoglobulin 609 repertoire sequencing data

Integrated pipeline for the accelerated discovery of antiviral antibody 611 therapeutics

Neutralizing and protective human monoclonal antibodies 613 recognizing the N-terminal domain of the SARS-CoV-2 spike protein

Structure-based design of prefusion-stabilized SARS-CoV-2 spikes

Automated electron microscope tomography using robust prediction 618 of specimen movements

cryoSPARC: algorithms for 620 rapid unsupervised cryo-EM structure determination